GLP-1 receptor agonists for obesity treatment

Current State

GLP-1 receptor agonists (GLP-1 RAs) are well-established for obesity treatment, leveraging their effects on glycemic control, gastric emptying, and appetite regulation (Nauck et al., 2017; Zhao et al., 2021). Semaglutide and liraglutide are prominent examples, with development efforts focused on extending half-life and improving delivery (Knudsen et al., 2019; Nauck et al., 2020). Dual agonists, such as tirzepatide (a GIP and GLP-1 RA), have shown superior efficacy in type 2 diabetes and are being investigated for obesity (Coşkun et al., 2018; Frías et al., 2021). Oral formulations like orforglipron represent a significant advancement in patient convenience (Wharton et al., 2025).

Strongest Evidence

Clinical trials consistently demonstrate significant weight loss with GLP-1 RAs. Semaglutide has shown efficacy in reducing cardiovascular events in patients with obesity and established cardiovascular disease, even without diabetes (Lincoff et al., 2023). Beyond weight loss, GLP-1 RAs exhibit broader metabolic benefits, including potential for treating nonalcoholic steatohepatitis (NASH) (Newsome et al., 2020). The mechanism involves widespread GLP-1 receptor distribution beyond the pancreas, influencing neuroinflammation and nerve growth (Zhao et al., 2021).

Unresolved Uncertainties

While generally safe, rare adverse events associated with GLP-1 RAs, such as suicidality and nonarteritic anterior ischemic optic neuropathy, require further investigation (McIntyre et al., 2023; Abbass et al., 2025). Long-term efficacy and safety data, particularly for newer compounds and oral formulations, are still accumulating. Optimal patient selection criteria and the comparative effectiveness of different GLP-1 RAs and dual agonists in diverse patient populations remain areas of ongoing research.

Why the Topic Matters

Obesity is a growing global health crisis associated with numerous complications and increased mortality (Wang et al., 2023). GLP-1 RAs offer a powerful therapeutic option for weight management and associated comorbidities, significantly improving patient health outcomes and reducing healthcare burdens. The development of more effective and convenient formulations, including oral options, expands accessibility and adherence, making these treatments crucial in the fight against obesity.

Points of Agreement

• GLP-1 RAs are highly effective for weight reduction in individuals with obesity, often leading to significant body weight loss (Wang et al., 2023; Zhao et al., 2021).
• GLP-1 RAs offer benefits beyond glycemic control, including improvements in cardiovascular outcomes, reduction of food intake, delayed gastric emptying, and regulation of lipid metabolism (Nauck et al., 2017; Zhao et al., 2021).
• Semaglutide and liraglutide are well-established GLP-1 RAs with documented efficacy and safety profiles for obesity and type 2 diabetes (Knudsen et al., 2019; Nauck et al., 2020).
• Dual agonists, such as tirzepatide (GIP and GLP-1 RA), demonstrate superior efficacy in glycemic control and weight loss compared to selective GLP-1 RAs like semaglutide (Frías et al., 2021; Coşkun et al., 2018).
• Oral formulations of GLP-1 RAs, like orforglipron, are emerging as promising alternatives to injectable forms, offering comparable efficacy in weight reduction (Wharton et al., 2025).

Active Disagreements

• The precise long-term cardiovascular benefits of GLP-1 RAs in patients with obesity without diabetes are still being investigated, though initial findings for semaglutide are positive (Lincoff et al., 2023).
• The association between GLP-1 RAs and rare adverse events, such as nonarteritic anterior ischemic optic neuropathy (NAION) and suicidality, requires further clarification and robust epidemiological studies (Abbass et al., 2025; McIntyre et al., 2023).

Uncertain Claims

• The full extent of GLP-1 RAs' protective effects on islet β cells and their long-term impact on disease progression in non-diabetic obesity remains to be fully elucidated (Zhao et al., 2021).
• The optimal patient selection criteria for different GLP-1 RA formulations (e.g., oral vs. injectable, mono vs. dual agonists) to maximize efficacy and minimize side effects are still being refined.

Evidence Gaps

• Long-term real-world evidence on the sustained weight loss and metabolic benefits of newer GLP-1 RAs and dual agonists in diverse patient populations is needed.
• Comparative effectiveness studies directly comparing all available GLP-1 RAs and dual agonists for obesity treatment, considering various patient subgroups and comorbidities, are limited.
• Research on the cost-effectiveness of GLP-1 RAs for obesity treatment, especially in the context of long-term use and prevention of obesity-related complications, is an ongoing area of need.
• Further investigation into the mechanisms underlying the non-pancreatic effects of GLP-1 RAs, such as their impact on neuroinflammation and heart function, is warranted (Zhao et al., 2021).

GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs demonstrating strong evidence for their efficacy in treating obesity and associated metabolic conditions. Their mechanism involves suppressing appetite, delaying gastric emptying, and regulating blood lipid metabolism (Zhao et al., 2021; Wang et al., 2023).

Efficacy in Weight Reduction and Metabolic Benefits:

• Strong Evidence: GLP-1 RAs, including semaglutide and liraglutide, consistently show significant weight loss in patients with obesity, with or without type 2 diabetes (Knudsen et al., 2019; Nauck et al., 2020). Semaglutide has also been shown to reduce cardiovascular risk in overweight and obese patients without diabetes (Lincoff et al., 2023). Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated superior efficacy in glycemic control and weight reduction compared to semaglutide in patients with type 2 diabetes (Frías et al., 2021; Coşkun et al., 2018).
• Supporting Evidence: Beyond weight loss, GLP-1 RAs contribute to improved glycemic control, protection of islet β cells, and potential benefits in conditions like nonalcoholic steatohepatitis (NASH) (Newsome et al., 2020; Zhao et al., 2021).

Formulations and Development:

• Strong Evidence: Various formulations exist, including once-daily (liraglutide, lixisenatide) and once-weekly injectable (semaglutide, dulaglutide) preparations. Oral semaglutide is also available (Nauck et al., 2020). Novel oral small-molecule GLP-1 RAs like orforglipron are under investigation, showing promising results for obesity treatment (Wharton et al., 2025).

Safety Profile and Limitations:

• Moderate Evidence: Common side effects are primarily gastrointestinal (e.g., nausea, vomiting, diarrhea). While generally well-tolerated, there are ongoing investigations into rare but serious adverse events.
• Conflicting/Emerging Evidence: Recent reports have prompted investigations into potential associations between GLP-1 RAs and suicidality (McIntyre et al., 2023) and nonarteritic anterior ischemic optic neuropathy (NAION) (Abbass et al., 2025). The evidence for these associations is currently being evaluated and is not yet conclusive. Previous research indicates cardioprotective actions and a reduction in cardiovascular events (Nauck et al., 2017).

Recent trends in GLP-1 receptor agonists (GLP-1 RAs) for obesity treatment are marked by several key developments, including novel formulations, the emergence of dual agonists, and an expanding understanding of their therapeutic applications beyond glycemic control.

Novel Formulations and Delivery Methods:

There is a significant trend towards developing more convenient and patient-friendly formulations. Oral small-molecule GLP-1 RAs are emerging as a promising alternative to injectables. For instance, orforglipron, a nonpeptide oral GLP-1 RA, is being investigated in phase 3 trials for obesity treatment in patients without diabetes, showing potential for once-daily administration (Wharton et al., 2025). This represents a shift from earlier injectable formulations like liraglutide and semaglutide, which were developed to extend the half-life of GLP-1 for therapeutic effectiveness (Knudsen et al., 2019; Nauck et al., 2020).

Dual GIP/GLP-1 Receptor Agonists:

Another significant trend is the development of dual agonists that target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown superior efficacy compared to selective GLP-1 RAs like semaglutide in patients with type 2 diabetes (Frías et al., 2021). The rationale behind these dual agonists is to leverage the synergistic metabolic actions of both incretin hormones to achieve greater weight loss and glycemic control (Coşkun et al., 2018).

Expanded Therapeutic Applications and Benefits:

GLP-1 RAs are increasingly recognized for their benefits beyond glucose regulation and weight loss. They have shown promise in reducing the risk of adverse cardiovascular events in patients with obesity, even in the absence of diabetes (Lincoff et al., 2023). Furthermore, GLP-1 RAs are being explored for other metabolic conditions, such as nonalcoholic steatohepatitis (NASH), with semaglutide demonstrating efficacy in phase 2 trials for patients with biopsy-confirmed NASH (Newsome et al., 2020). The widespread distribution of GLP-1 receptors beyond the pancreas suggests multiple biological effects, including appetite suppression, delayed gastric emptying, and potential improvements in heart function and neuroinflammation (Zhao et al., 2021; Nauck et al., 2017).

Safety and Adverse Event Monitoring:

While GLP-1 RAs are generally well-tolerated, ongoing research is focused on monitoring and understanding potential adverse events. Recent reports have prompted investigations into the association between GLP-1 RAs (liraglutide and semaglutide) and suicidality (McIntyre et al., 2023). Additionally, studies are examining the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed GLP-1 RAs (Abbass et al., 2025). These investigations are crucial for ensuring the long-term safety of these widely used medications.

Synthesis

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a primary pharmacological intervention for obesity. These agents mimic the endogenous incretin hormone GLP-1, promoting weight loss by suppressing appetite, delaying gastric emptying, and improving glycemic control (Wang et al., 2023; Zhao et al., 2021). The development from short-acting to long-acting analogs like liraglutide and semaglutide has enhanced their therapeutic utility (Knudsen et al., 2019; Nauck et al., 2020). Beyond weight loss, GLP-1 RAs confer significant cardiovascular benefits, reducing adverse events in patients with obesity even without diabetes (Lincoff et al., 2023; Nauck et al., 2017). The therapeutic landscape is rapidly evolving with the introduction of dual-agonists, such as tirzepatide (a GIP and GLP-1 RA), which has demonstrated superior efficacy in weight reduction compared to semaglutide alone in patients with type 2 diabetes (Frías et al., 2021; Coşkun et al., 2018).

Methods & Materials

The efficacy and safety of GLP-1 RAs are primarily established through large-scale, randomized, double-blind, placebo-controlled trials. For example, the development of the oral small-molecule GLP-1 RA, orforglipron, was assessed in a phase 3 trial measuring percent change in body weight from baseline over 72 weeks as the primary endpoint (Wharton et al., 2025). Similarly, the cardiovascular benefits of semaglutide in non-diabetic obese patients were confirmed in a multicenter, event-driven superiority trial (Lincoff et al., 2023). Safety signals are often evaluated using retrospective cohort studies and analyses of adverse event reporting systems, such as the FDA's FAERS database to investigate links to suicidality (McIntyre et al., 2023) and the TriNetX network to assess the risk of nonarteritic anterior ischemic optic neuropathy (NAION) (Abbass et al., 2025).

Applications

GLP-1 RAs are approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity. Their application extends beyond weight loss to include risk reduction for major adverse cardiovascular events (Lincoff et al., 2023). They are also being investigated for other obesity-related conditions, such as nonalcoholic steatohepatitis (NASH), where semaglutide has shown potential for resolving the condition without worsening fibrosis (Newsome et al., 2020).

Limitations

Despite their efficacy, GLP-1 RAs are associated with common gastrointestinal side effects. More serious, though less frequent, safety concerns are under investigation. Analysis of the FAERS database showed reports of suicidality associated with GLP-1 RAs, prompting regulatory review, although a causal relationship has not been established (McIntyre et al., 2023). A retrospective cohort study also explored a potential association with NAION, an ischemic optic condition, highlighting the need for continued pharmacovigilance (Abbass et al., 2025). The high cost and need for long-term, often injectable, administration can also be barriers to access and adherence.

Update Triggers

Future updates to this review will be triggered by: 1) The release of long-term data from ongoing cardiovascular outcome trials for newer agents like orforglipron and tirzepatide in obesity. 2) Definitive conclusions from regulatory bodies (e.g., FDA, EMA) regarding the investigation into suicidality risks. 3) Head-to-head trial results comparing novel oral GLP-1 RAs and dual-agonists directly for obesity treatment. 4) New research clarifying the mechanisms and incidence of rare but serious adverse events.

Near-Term Work

The immediate research focus should be on comparative effectiveness trials and expanding therapeutic indications. High-priority studies include direct head-to-head comparisons of novel dual-agonists (e.g., tirzepatide) against established GLP-1 RAs like semaglutide to clarify superior efficacy in weight loss and glycemic control (Frías et al., 2021). Further investigation into the efficacy of GLP-1 RAs for obesity-related comorbidities, particularly nonalcoholic steatohepatitis (NASH), is crucial (Newsome et al., 2020). Research should also prioritize the development and testing of new formulations, such as oral agents, to improve patient adherence and convenience (Nauck et al., 2020).

Validation Needs

Long-term data is paramount. While short-term efficacy is well-documented, longitudinal studies extending beyond typical trial durations (e.g., >2 years) are needed to validate the sustainability of weight loss, long-term safety, and impact on cardiovascular morbidity and mortality in diverse, real-world populations. Furthermore, the mechanisms underlying inter-individual variability in treatment response and side effects require robust validation to enable personalized medicine approaches.

Datasets & Benchmarks

Establishing large-scale, multi-center patient registries is essential. These datasets should capture longitudinal data on weight, metabolic parameters, adverse events, and patient-reported outcomes from individuals on various GLP-1 RAs. Standardized benchmarks for treatment success should be defined beyond simple percentage weight loss, incorporating metrics for metabolic health improvement and quality of life. These registries will be critical for generating real-world evidence.

Translation Barriers

The primary barriers to widespread clinical translation are cost and access. The high price of these medications limits their availability, creating significant socioeconomic disparities in obesity care. Another barrier is managing common gastrointestinal side effects, which can lead to treatment discontinuation. Public and private payer coverage policies often restrict use, posing a significant hurdle to integrating these effective treatments into standard clinical practice (Wang et al., 2023).

High-Value Experiments

High-value experiments include mechanistic studies to identify biomarkers that predict patient response and susceptibility to adverse effects. Investigating combination therapies, such as pairing GLP-1 RAs with agents targeting different pathways, could yield synergistic effects and is a high-priority experimental avenue. Additionally, trials designed to understand the optimal strategies for treatment tapering or discontinuation after achieving weight loss goals are needed to inform long-term management.